Page last updated: 2024-10-30

maprotiline and Multiple Sclerosis

maprotiline has been researched along with Multiple Sclerosis in 1 studies

Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Feuerstein, TJ1

Other Studies

1 other study available for maprotiline and Multiple Sclerosis

ArticleYear
Beneficial effects of maprotiline on irritative urinary symptoms in multiple sclerosis.
    Lancet (London, England), 1988, Dec-10, Volume: 2, Issue:8624

    Topics: Adult; Anthracenes; Drug Evaluation; Female; Humans; Male; Maprotiline; Middle Aged; Multiple Sclero

1988